4 ms·

The pricing issue of gene therapy is quite interesting. A comparable treatment which is licensed now (Zolgensma, Novartis), has an estimated price tag of $2 mil

• s1artibartfast 8y ago
  Interesting indeed. Would you say that this is price is unreasonably high? If I am reading the following article correctly, the target patient population for Zolgensma experience an average of 4.2 hospitalizations a year with a mean cost of $150K per hospitalization (2012 dollars and rates) https://link.springer.com/article/10.1007/s41669-018-0093-0 https://link.springer.com/article/10.1007/s41669-018-0093-0